TAL Education Group's stock soared following a remarkable fiscal Q3 2026 report, showcasing a dramatic turnaround to profitability and robust revenue growth, fueled by strategic investments in educational technology.
Apple's Q1 earnings smashed expectations, fueled by surging iPhone sales and robust performance in China. While CEO Tim Cook's operational prowess is undeniable, the company's muted AI strategy and reliance on a Google partnership left investors wanting more.
LendingClub Corp. (LC) shares tumbled sharply this week, extending losses for a third consecutive session after the company announced a shift to fair value accounting. The move, aimed at aligning revenue with credit costs, spooked investors despite the fintech firm reporting a 164% surge in annual net income.
Shares of warehouse automation leader Symbotic tumbled sharply ahead of its Q2 2026 earnings report, as investors grapple with insider selling activity and questions over its premium valuation. The upcoming guidance on revenue growth and margins is seen as a critical test for the stock's near-term direction.
Netflix delivered solid Q4 earnings but saw its stock dip as it guided for slower revenue growth. The streaming giant's strategic pivot to a mature phase is underscored by its aggressive all-cash bid for Warner Bros. Discovery, a move that promises content dominance but adds significant debt.
A deep dive into Pantech Group Holdings Berhad's valuation using a Discounted Cash Flow model suggests the stock may be trading close to its intrinsic value, offering investors a potential entry point in the industrial supplies sector.
Southeast Asian super app Grab Holdings has appointed Laura Franco to its board, succeeding the retiring Ng Shin Ein. The move signals a governance refresh aimed at steering the company's aggressive expansion into on-demand grocery, financial technology, and next-generation mobility partnerships.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
As investors navigate a complex economic landscape, companies with significant insider ownership and robust earnings forecasts are drawing attention. We examine three ASX-listed firms where leadership's skin in the game aligns with ambitious growth projections.
M/I Homes' latest financial results reveal a year of softer earnings and margin pressure, even as the company completed a significant share repurchase. This mixed picture is prompting investors to reassess the homebuilder's near-term growth trajectory and the sustainability of its capital return strategy.
Arlo Technologies has registered over 4.2 million shares for an employee stock plan, a move that brings potential dilution and the company's capital strategy into focus as its stock shows signs of cooling momentum after a strong run.
ASML Holding NV has launched a massive new share repurchase program and reaffirmed strong sales guidance, as record AI-related equipment orders fuel optimism about the Dutch tech giant's central role in the semiconductor industry's future.
While Boise Cascade's five-year total shareholder return of 110% has significantly outperformed its modest earnings growth, the building materials firm's recent stock slump raises questions about its valuation and future trajectory in a volatile market.
Investment firm CapWealth Advisors has significantly increased its stake in telecom provider Lumen Technologies, signaling confidence amid the company's strategic pivot towards enterprise and AI infrastructure.
German biotech firm AMSilk partners with Italian mill Pure Denim to launch a new category of high-performance, sustainable denim infused with lab-grown spider silk proteins, targeting the luxury market with enhanced comfort and eco-credentials.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Investment firm Ashva Capital Management reveals Micron Technology as its largest holding in its latest investor letter, detailing a conviction play on the memory chip giant's long-term trajectory amid AI-driven demand and market volatility.
ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.
